Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial

医学 卡铂 紫杉醇 阿维鲁单抗 肿瘤科 打开标签 子宫内膜癌 内科学 化疗 随机对照试验 癌症 免疫疗法 顺铂 无容量
作者
Sandro Pignata,Giovanni Scambia,Clorinda Schettino,Laura Arenare,Carmela Pisano,Davide Lombardi,Ugo De Giorgi,Claudia Andreetta,Saverio Cinieri,Carmine De Angelis,Domenico Priolo,Cláudia Casanova,Marta Rosati,Filippo Greco,Elena Zafarana,Ilaria Schiavetto,Serafina Mammoliti,Sabrina Chiara Cecere,Vanda Salutari,Simona Scalone,Alberto Farolfi,Marilena Di Napoli,Domenica Lorusso,Piera Gargiulo,Daniela Califano,Daniela Russo,Anna Spina,Rossella De Cecio,Paolo Chiodini,Francesco Perrone,Valentina Accinno,Chiara Altavilla,Claudia Andreetta,Giovanna Antonelli,Laura Arenare,Grazia Artioli,Francesco Avola,Bonifacio Barbara,Valentina Barbato,Michele Bartoletti,Simona Bevilacqua,Roberto Bordonaro,Oriana Borghese,Gaetano Buonfanti,Daniela Califano,Floriana Camarda,Giuliana Canzanella,Maria Rita Carbone,Maria Rita Carbone,G Stella,Cláudia Casanova,Chiara Cassani,Fabrizio Castagna,Monica Cattaneo,Sabrina Chiara Cecere,Paolo Chiodini,M. Cinefra,Saverio Cinieri,Nicoletta Colombo,Serena Corsetti,Monia Dall’Agata,Maria Rosaria D’Amico,Gennaro Daniele,Carmine De Angelis,Rossella De Cecio,Ugo De Giorgi,Elvira De Marino,Giovanni De Matteis,Sabino De Placido,Gabriella Del Bene,Antonia Del Giudice,Francesca Del Monte,Michele Del Sesto,Marilena Di Napoli,Maddalena Donini,Giuliana Drudi,G Falcone,Alberto Farolfi,Adolfo Favaretto,Giulia Ferrera,Manuela Florio,Valeria Forestieri,Maria Stella Gallo,Ciro Gallo,Piera Gargiulo,Francesca Garibaldi,Fabiana Gerevini,Viola Ghizzoni,Maria Olga Giganti,Anna Gimigliano,Elena Giudice,Nicoletta Gnocchi,Adriano Gravina,Filippo Greco,Stefano Greggi,Maria Laura Iaia,Annalisa Ilardi,Gelsomina Iovine,Gabriella Ippoliti,Giulia Irollo,Ilenia Isidori,Mariateresa Lapresa,G. Lavenia,Davide Lombardi,Laura Longhitano,Domenica Lorusso,Bortot Lucia,Gabriella Luzi,Serafina Mammoliti,Sara Mariano,Valentina Marino,Giovanna Marrapese,Marilena Martino,Roberta Matocci,E. Mazzoni,Daniela Mercuri,Maria Mirto,Giovanna Mollo,A. Montinaro,Marta Moscatelli,Anna Maria Mosconi,Lucia Musacchio,Nicoletta Nanni,Pamela Natalucci,Milena S. Nicoloso,Michele Orditura,Gabriella Maria Parma,Rodolfo Passalacqua,Michela Pelone,Maria Teresa Perri,Francesco Perrone,Bruno Perrucci,A Piancastelli,Maria Carmela Piccirillo,Antonio Piccolo,Sandro Pignata,Carmela Pisano,Domenico Priolo,Stefania Rapisardi,Giorgia Ravaglia,Teresa Ribecco,Caterina Ricci,Marianna Roccio,Fiorella Romano,Marta Rosati,Daniela Russo,Vanda Salutari,Daniela Sambataro,Alfonso Savio,Ada Sbriglia,Cono Scaffa,Simona Scalone,Giovanni Scambia,Clorinda Schettino,Ilaria Schiavetto,Concetta Sergi,Francesca Sgandurra,Roberto Sorio,Anna Spina,Stefano Stabile,Gianna Tabaro,Margherita Tambaro,Stefano Tamberi,Angelica Tecchiato,Ángela Maria Trujillo,Eleonora Zaccarelli,Elena Zafarana
出处
期刊:Lancet Oncology [Elsevier]
卷期号:24 (3): 286-296 被引量:13
标识
DOI:10.1016/s1470-2045(23)00016-5
摘要

Summary

Background

Adding immunotherapy to first-line chemotherapy might improve outcomes for patients with advanced or recurrent endometrial cancer. We aimed to compare carboplatin and paclitaxel versus avelumab plus carboplatin and paclitaxel as first-line treatment with avelumab given concurrent to chemotherapy and as maintenance after the end of chemotherapy.

Methods

MITO END-3 is an open-label, randomised, controlled, phase 2 trial conducted at 31 cancer institutes, hospitals, and universities in Italy. Eligible patients were aged 18 years or older with histologically confirmed advanced (FIGO stage III–IV) or recurrent endometrial cancer, an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1, and no previous systemic anticancer therapy as primary treatment for advanced or metastatic disease. Participants were randomly assigned (1:1) using a computerised minimisation procedure stratified by centre, histology, and stage at study entry, to either receive carboplatin (area under the curve [AUC] 5 mg/mL × min) and paclitaxel (175 mg/m2; standard group) intravenously every 3 weeks for six to eight cycles or avelumab (10 mg/kg intravenously) added to carboplatin and paclitaxel (experimental group) every 3 weeks and then every 2 weeks as a single maintenance treatment after the end of chemotherapy until disease progression or unacceptable toxicity. Patients, treating clinicians, and those assessing radiological examinations were not masked to study treatment. The primary endpoint was investigator-assessed progression-free survival, measured in the intention-to-treat (ITT) population. Patients who received at least one dose of study drug were included in the safety analysis. Experimental group superiority was tested with 80% power and one-tailed α 0·20. This trial is registered with ClinicalTrials.gov (NCT03503786) and EudraCT (2016–004403–31).

Findings

From April 9, 2018, to May 13, 2021, 166 women were assessed for eligibility and 39 were excluded. 125 eligible patients were randomly assigned to receive carboplatin and paclitaxel (n=62) or avelumab plus carboplatin and paclitaxel (n=63) and included in the ITT population. The median follow-up was 23·3 months (IQR 13·2–29·6) and was similar between the two groups. 91 progression-free survival events were reported, with 49 events in 62 patients in the standard group and 42 events in 63 patients in the experimental group. The median progression-free survival was 9·9 months (95% CI 6·7–12·1) in the standard group and 9·6 months (7·2–17·7) in the experimental group (HR of progression or death 0·78 [60% CI 0·65–0·93]; one-tailed p=0·085). Serious adverse events were reported more frequently in the experimental group (24 vs seven events in the standard group); neutrophil count decrease was the most frequent grade 3–4 adverse event (19 [31%] of 61 patients in the experimental group vs 26 [43%] of 61 patients in the standard group). Two deaths occurred in the experimental group during treatment (one respiratory failure following severe myositis [possibly related to treatment] and one cardiac arrest [not related to treatment]).

Interpretation

Adding avelumab to first-line chemotherapy deserves further testing in patients with advanced or recurrent endometrial cancer, although consideration of mismatch repair status is warranted.

Funding

Pfizer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
lefora完成签到,获得积分10
1秒前
InfoNinja完成签到,获得积分0
1秒前
zxc完成签到,获得积分10
1秒前
juice完成签到 ,获得积分10
1秒前
黑色幽默完成签到,获得积分10
1秒前
1秒前
忐忑的雪糕完成签到 ,获得积分10
4秒前
黑色幽默发布了新的文献求助10
4秒前
fabian完成签到,获得积分10
5秒前
噼里啪啦完成签到,获得积分10
5秒前
DT完成签到,获得积分10
5秒前
zxc发布了新的文献求助10
6秒前
稳重岩完成签到 ,获得积分10
6秒前
TT完成签到,获得积分10
6秒前
wanglu完成签到,获得积分10
7秒前
mojito完成签到 ,获得积分10
8秒前
LingYun完成签到,获得积分10
8秒前
等待戈多发布了新的文献求助10
10秒前
要减肥的惜梦完成签到 ,获得积分10
11秒前
Kalimba完成签到,获得积分10
12秒前
修水县1个科研人完成签到 ,获得积分10
12秒前
昵称什么的不重要啦完成签到 ,获得积分10
13秒前
张西西完成签到 ,获得积分10
13秒前
思源应助Islet采纳,获得10
14秒前
Joy完成签到,获得积分10
15秒前
Casey完成签到 ,获得积分10
16秒前
Skyrin完成签到,获得积分10
16秒前
Sunny完成签到,获得积分10
16秒前
17秒前
火星上白羊完成签到,获得积分10
18秒前
米共完成签到 ,获得积分10
21秒前
国靖发布了新的文献求助10
22秒前
在水一方应助科研通管家采纳,获得10
22秒前
虚心的清完成签到,获得积分10
22秒前
SH完成签到,获得积分10
23秒前
白杨完成签到 ,获得积分10
25秒前
xuening完成签到,获得积分10
26秒前
在水一方应助lili采纳,获得10
26秒前
俭朴的世界完成签到 ,获得积分10
27秒前
高分求助中
Sustainability in Tides Chemistry 2000
Microlepidoptera Palaearctica, Volumes 1 and 3 - 13 (12-Volume Set) [German] 1122
Дружба 友好报 (1957-1958) 1000
The Data Economy: Tools and Applications 1000
Mantiden - Faszinierende Lauerjäger – Buch gebraucht kaufen 700
PraxisRatgeber Mantiden., faszinierende Lauerjäger. – Buch gebraucht kaufe 700
A Dissection Guide & Atlas to the Rabbit 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3099819
求助须知:如何正确求助?哪些是违规求助? 2751306
关于积分的说明 7612410
捐赠科研通 2403104
什么是DOI,文献DOI怎么找? 1275188
科研通“疑难数据库(出版商)”最低求助积分说明 616276
版权声明 599053